viDA Therapeutics is a biopharmaceutical company focused on the development of therapeutics based on inhibition of a family of serine proteases, known as Granzymes.

        Granzymes are implicated in a wide range of diseases and unmet medical conditions. Our lead program is focussed on developing specific inhibitors for the treatment of chronic tissue injury and improvement of chronic wound healing, areas of key patient need.

        Targeting Granzyme inhibition is a novel approach and represents a new paradigm in treatment of chronic wounds.